The Digital Pen: AI Rewrites the Script for Alzheimer's Diagnosis

BOSTON, MA – July 08, 2026 – For decades, the clock-drawing test has been a staple of cognitive screening—a simple, pen-and-paper task to flag potential dementia. But what if the pen itself held the data? What if every pause, tremor, and stroke could be analyzed by an AI to reveal subtle signs of cognitive decline years before a traditional diagnosis? This is no longer a futuristic concept; it's the new reality being forged by companies like Linus Health.

As the medical community prepares for the upcoming Alzheimer's Association International Conference (AAIC) in London, the atmosphere is charged with a new urgency. The recent arrival of FDA-approved, disease-modifying therapies has fundamentally altered the landscape of Alzheimer's care. These treatments are most effective in the disease's earliest stages, turning early and accurate detection from a clinical ideal into an absolute necessity. With an estimated 7.4 million Americans aged 65 and older living with Alzheimer's in 2026, the pressure on healthcare systems to identify the right patients at the right time is immense.

Boston-based Linus Health is stepping into this high-stakes environment with a suite of digital tools designed to do just that. At AAIC, the AI-driven brain health company will present research on three fronts that address the industry's most pressing challenges: identifying patients earlier, measuring outcomes that actually matter to them, and arming primary care physicians with the precision of a specialist.

"The arrival of disease-modifying treatments has raised the stakes for accurate, accessible digital cognitive assessments," said David Bates, PhD, CEO and co-founder of Linus Health. "Our AAIC 2026 research shows how validated, AI-enabled digital tools that capture not only whether a patient completes a task, but how they complete it, can help identify the right patients earlier."

A Smarter Screen: From 'What' to 'How'

For years, clinicians have relied on screening tools like the Montreal Cognitive Assessment (MoCA). While valuable, these tests provide a single score—a snapshot in time that can be influenced by education level, anxiety, or simply a bad day. They primarily measure the 'what'—the final answer—but miss the rich data hidden in the 'how.'

Linus Health's research, to be presented by its Director of Cognitive Science, Ali Jannati, MD, PhD, highlights the superior performance of its flagship tool, the Digital Clock and Recall (DCR™). In a real-world clinical study, the DCR™ outperformed the MoCA in detecting mild cognitive impairment (MCI), demonstrating not only higher accuracy but substantially greater specificity. This is critical for reducing the number of false positives—healthy individuals who are incorrectly flagged, leading to unnecessary anxiety and costly follow-up testing.

The DCR™ achieves this by using a digital stylus on a tablet to capture thousands of data points during the clock-drawing task. The AI analyzes everything from the speed of the pen and the length of pauses to the sequence of drawing the numbers. This granular analysis of the process, combined with a verbal recall test, provides a far more sensitive digital biomarker of cognitive function. When combined with the company's Amyloid Positivity Risk model, the platform becomes a powerful tool for flagging individuals with MCI who are likely to have underlying Alzheimer's pathology—the very population that may benefit from new therapies.

"Identifying who is most likely to benefit from a disease-modifying therapy is one of the most pressing challenges in Alzheimer's care," Jannati explained. "By combining the DCR Cognition Score with our Amyloid Positivity Risk model, we can help flag individuals... in a matter of minutes, helping clinicians and trial teams focus their efforts where they may matter most."

Beyond Biomarkers: Measuring What Matters

While identifying the disease early is a monumental step, another question looms large: how do we define a successful treatment? For a person living with early Alzheimer's, success isn't just a change in a biomarker; it's the ability to continue managing their finances, to keep up with grandchildren, or to stay composed in a conversation.

This is where Linus Health's second innovation, the electronic Person-Specific Outcome Measure (ePSOM), comes into play. Moving beyond standardized checklists, ePSOM is a free-text, individualized questionnaire. It allows patients to articulate, in their own words, the everyday abilities and priorities that are most meaningful to them. This provides a personalized benchmark against which the true benefit of a therapy can be measured.

Research led by Stina Saunders, PhD, the company's Personalized Medicine Lead, demonstrated the feasibility of deploying ePSOM in Japan. The tool proved effective in a distinct cultural and clinical setting without needing structural changes, supporting its potential for use in global clinical trials. This innovation allows drug developers and regulators to see if a therapy is improving the things that patients and their families actually care about.

"Treatment benefit means something different to every person," said Saunders. "When a measure travels across very different health systems and cultures and still reflects those individual priorities, it gives drug developers and regulators a more honest picture of whether a therapy is improving the things people actually care about."

The Challenge of a New Clinical Reality

These technological advancements represent a paradigm shift, but their journey from the research poster to the primary care clinic is fraught with practical challenges. The promise of digital health can only be realized if it is accessible, affordable, and seamlessly integrated into existing workflows. Healthcare systems already face the high cost of new Alzheimer's drugs; adding the expense of new diagnostic software, hardware, and training presents a significant hurdle.

Furthermore, the digital divide remains a stark reality. For these tools to be truly equitable, they must be usable by older adults with varying levels of technological literacy and accessible to those in underserved communities who may lack reliable internet or personal devices. Experts caution that without a concerted effort to address reimbursement, EHR interoperability, and digital equity, these powerful innovations could inadvertently widen healthcare disparities.

Linus Health's work is part of a massive wave of innovation set to be showcased at AAIC 2026. It joins a chorus of companies like Roche, Eisai, and Quanterix, all racing to refine diagnostics through blood-based biomarkers, advanced imaging, and digital tools. This collective push is transforming Alzheimer's from a disease you wait to diagnose into a condition you proactively manage. The shift is monumental, moving the entire field closer to a future where brain health is monitored with the same regularity as blood pressure, powered by technology that understands not just what we do, but precisely how we do it.